In all, 451 myeloma patients, 51% previously untreated, underwent elective single autotransplantation after 200 mg/m 2 melphalan between 1985 and 2001 at the Royal Marsden Hospital. The therapy sequence was: Induction (vincristine, doxorubicin, methylprednisolone7cyclophosphamide), marrow or filgrastim-mobilized blood stem cell harvest, autograft, and interferon-a2b maintenance. A total of 27 (6%) died of transplant-related toxicity, all within 3 months. Complete or near-complete remission was seen in 59% with an overall response rate of 91%. Subsequent disease progression was seen in 285, and 17 died of unrelated causes. In all, 206 patients were alive at the last follow-up, 6 months to 17.7 years posttransplant (median 65 months); 122 without disease progression at 6 months to 17.7 years (median 58 months). The median overall (OS) and event-free (EFS) survivals were 5.9 and 2.4 years, with 10-year OS and EFS probabilities of 31.4 and 16.5%, respectively. In Cox analysis, it was seen that significantly longer OS occurred for patients who had b-2-microglobulin o3.5 mg/l (Po0.0001), age o60 years (P ¼ 0.001) and albumin X35 g/l (P ¼ 0.009). EFS was also longer if b-2-microglobulin was o3.5 mg/l (P ¼ 0.0056) and patients were o60 years of age (P ¼ 0.033). We conclude that with a single planned autograft, patients with myeloma have an excellent outcome.
It is now 20 years since high-dose melphalan (HDM) confirmed proof of principle that dose escalation of an alkylating agent could exponentially lead to an increased antitumor effect in myeloma 1 and this increase in dose has been exploited further by increasing the dose of melphalan with stem cell rescue 2, 3 and use of tandem autotransplants. 4 Since it fulfills the requirements of evidence-based medicine, single autotransplants following induction have now become standard treatment for younger and new patients with myeloma. 5, 6 The major question in myeloma therapy today is probably one of single vs tandem autotransplantation. The Arkansas group has advocated tandem autografts strongly and a recent French prospective study suggested that tandem autotransplantation was superior to single, other prospective studies have not shown tandem autotransplants to be superior in terms of overall survival (OS). 4, [7] [8] [9] The Royal Marsden Hospital (RMH) series is the world's largest single-center experience of elective single autografts performed as consolidation therapy in myeloma after a uniform conditioning regimen (200 mg/m 2 melphalan). This analysis was undertaken to present mature data from this series showing the outcome of single autografts in myeloma.
Patients and methods
Prospectively gathered data 10 were analyzed on 451 consecutive myeloma patients who were autografted after initial induction chemotherapy using 200 mg/m 2 melphalan as the conditioning regimen between February 1985 and October 2001 at the Royal Marsden Hospital. Prior to the autograft, 232 (51%) were untreated and received induction at RMH while 219 received induction at referring hospitals. None of these patients were planned to receive a tandem transplant. Data on some of these patients has previously been reported elsewhere. 2, 3, [11] [12] [13] [14] [15] Patients provided informed consent for the therapy, and experimental protocols were approved by the institutional review board.
Response criteria
Paraprotein and immunoglobulin levels were estimated regularly to assess response, and bone marrow examination was performed as needed. Patients with clearly progressive bone disease before the transplant were classified as nonresponders. The response criteria have been described before, 16 and were as follows:
Complete remission (CR): Disappearance of monoclonal protein from serum and urine by immunoelectrophoresis with a normal bone marrow (o5% plasma cells); sustained for 3 months. Immunofixation-negativity was not required to define CR. This is the most vital difference between the response criteria used here and those proposed by Blade et al 17 Since the proportion of patients in CR with a negative immunofixation is overestimated by immunoelectrophoresis, this category has been referred to as 'CR/ near-CR' throughout this analysis.
Partial response (PR): 50% reduction in the quantity of monoclonal protein (50% reduction in marrow infiltration in patients with nonsecretory disease); sustained for 1 month.
Relapse: Reappearance of paraprotein or 45% plasma cells in the marrow for patients in CR, 25% increase in paraprotein on two occasions a month apart for patients in PR, or progressive bone disease.
Patients experiencing o50% reduction in paraprotein (or marrow plasmacytosis in case of nonsecretory disease) were considered to be nonresponders (NR).
Patients were considered to be in continued complete remission (CCR) or continued partial remission (CPR) if the CR/PR status attained after the induction chemotherapy continued post-autograft.
Maximum response was defined as either attainment of CR or a plateau phase for patients in PR (maximum reduction of the myeloma response criteria parameters).
Treatment plan
Patients treated elsewhere received a variety of regimens; alkylating agent based, infusional, or both. Those presenting without prior therapy received continuous-infusion VAMP (vincristine, doxorubicin, methylprednisolone) or C-VAMP (cyclophosphamide, vincristine, doxorubicin, methylprednisolone) chemotherapy every 3 weeks for one cycle beyond maximum response. A small proportion of C-VAMP-treated patients also received verapamil. 13 Prior to 1993, patients underwent bone marrow harvest from the iliac crests under general anesthesia once stable plateau was achieved. From 1993, stem cells were mobilized with 12-16 mg/kg G-CSF (rounded off to the nearest 300 or 480 mg vial size) and collected by leukapheresis. This was performed irrespective of disease status 12 and the extent of marrow infiltration with plasma cells. Marrow or blood stem cells were cryopreserved without further manipulation.
Melphalan was administered as a single dose of 200 mg/ m 2 4-6 weeks after completing chemotherapy, and stem cells were infused 24 h later. No growth factors were routinely administered post transplant to accelerate hematologic recovery other than in patients with renal dysfunction or in those with life-threatening neutropenic sepsis.
From 1988 onwards, after adequate marrow recovery had occurred (usually leukocytes 43 Â 10 9 /l and platelets 450 Â 10 9 /l), subcutaneous interferon-a2b was started at the dose of 3 MU/m 2 thrice a week and was continued until disease progression.
14 Initially this took place as part of a randomized trial. The dose of interferon was reduced or stopped according to the full blood count or other toxic manifestations.
Treatment at relapse was variable, and included C-VAMP, second autografts using cells collected after relapse and reinduction, thalidomide, other salvage chemotherapy, or allografts.
Statistical analysis
All follow-up data are current as of October 2003. The w 2 test was used to compare categoric variables and the Wilcoxon rank-sum test was used to compare continuous variables. Probabilities of event-free survival (EFS) and OS were estimated by the Kaplan-Meier method, and compared using the log-rank test. Cumulative incidence of transplant-related mortality (TRM) and relapse was estimated using each type of event as a risk competing for the other. Deaths due to other causes (myelodysplasia, other malignancies, stroke) were considered competing events for TRM and relapse, and patients dying of such causes were considered events for estimating EFS and OS. EFS and OS were calculated from the date of high-dose therapy.
The following factors were analyzed in univariate fashion for effect on, relapse, EFS and OS: sex, age (o60 vs X60 years), isotype (IgG vs IgA vs other), stage (III vs other), disease stage at autotransplant (CR vs rest), serum creatinine at transplant (480 vs p80 mmol/l), serum albumin at transplant (o35 vs X35 g/l) and serum b2-microglobulin at transplant (o3.5 vsX3.5 mg/dL).
Four patients with missing b2-microglobulin values were excluded from the Cox analyses. 18, 19 Eight patients proceeding to transplant without prior induction therapy 15 were classified as having unresponsive disease for the purposes of Cox analysis. Table 1 shows patient characteristics and Figure 1 shows patient flow through therapy. In all, 51 patients had cytogenetics performed by karyotyping , of whom eight patients had deletion 13. In all 27 patients (6%) died of transplant-related causes, all within 3 months -three of the patients were on dialysis at the time of transplant (Figure 2 ). In all, 11 of the 27 deaths were in the 90 (12%) patients with unresponsive or untreated disease died compared with 16 of 361 (4.5%) with responsive disease (P ¼ 0.006) at the time of autotransplant. Patients in the PBSC group were significantly older (Po0.0001), had a higher creatinine (P ¼ 0.01), higher b 2 -microglobulin (Po0.0001) and lower serum albumin (P ¼ 0.04).
Results

Response
Overall, 266 patients (59%) attained or maintained CR/ near-CR after the transplant. An additional 141 patients (31%) attained or maintained PR, whereas 17 patients (4%) had no response and had active disease at the time of autotransplant (Figure 1) . Two of the nonresponders were Single autograft with high-dose melphalan B Sirohi et al allografted shortly after autotransplantation and both died of allograft-related toxicity.
Relapse
Progressive disease was seen in 285 patients at 2 months to 14 years (median 1.9 years) (Figure 2 ). The cumulative incidence of disease progression was 80% at 10 years. Interestingly, two patients relapsed after being in first complete remission for 10.5 and 14 years (both received marrow rescue); both these patients are alive and well; one has entered partial remission with melphalan alone and the other continues on interferon maintenance with a low level of paraprotein. At the time of relapse, 218 patients were treated as follows: 144 received CVAMP, three received low-dose cyclophosphamide, nine received oral melphalan, 20 received oral idarubicin, 10 received thalidomide, six received the AHM monoclonal antibody, 10 patients received other regimens, 12 patients received autotransplants with the cells stored while they were in CR/near-CR, four patients went straight ahead with an allograft without prior reinduction. Eventually, 131 of the relapsing patients underwent second high-dose therapy (11 allografts and one melphalan 140 mg/m 2 alone) of which 119 (26%) were autografts (108 with melphalan 200 mg/m 2 , 11 other regimens).
A total of 14 patients died of unrelated causes such as myelodysplasia (n ¼ 2), acute myeloid leukemia (n ¼ 1), and other concomitant medical problems (n ¼ 11).
Source of cells
For autotransplantation, 303 patients received peripheral blood stem cell rescue (PBSC) and 148 received bone marrow rescue. A total of 118 of 148 (80%) marrow autotransplant patients relapsed at 2 months to 14 years (median 2.2 years) compared to 167 of 303 (55%) PBSC autotransplant patients who relapsed at 2 months to 8.8 years (median 3.2 years); P ¼ 0.02.
Survival
In all, 206 patients were alive at the last follow-up 6 months to 17.7 years posttransplant; 122 without disease progres- Single autograft with high-dose melphalan B Sirohi et al sion at 6 months to 17.7 years (median 58 months) ( Figure 3 ). Five overseas patients were lost to follow-up at a median of 8 months (range, 6-12 months) and were censored at the time of last clinic visit. The median OS and EFS were 5.9 and 2.4 years. The actuarial 5-year probabilities of OS and EFS were 57 and 32%, respectively. The actuarial 10-year probabilities of OS and EFS were 31.4 and 16.5%, respectively ( Figure 3 ). The single death occurring at 14.5 years in a patient in first CR ( Figure 3 ) was the result of a dissecting aortic aneurysm.
Cox analysis
As Table 2 shows, age o60 years, b2-microglobulin o3.5 mg/l and albumin X35 g/l, were found to be favorable factors for OS, whereas only age o60 years and b2-microglobulin o3.5 mg/l influenced EFS favorably. 
Discussion
This report provides the longest available follow-up of autotransplantation in myeloma using high-dose melphalan, which is now considered the standard conditioning regimen for myeloma. The results are encouraging with almost 30% of the patients projected to be alive a decade after the transplant. With the availability of effective salvage therapy such as thalidomide and bortezomib, agents, which were not available for the vast majority of patients in this series, an increase in the proportion of patients surviving longterm can be expected. 20, 21 The shortcomings of these data must be acknowledged. There was a certain amount of patient selection because of referral bias for younger patients (median 53 years). However, as a comparison with patient characteristics from the Arkansas series 4, 22 shows (median age 53 vs 51 years, Stage III disease 73 vs 53%, IgG 63 vs 61%), the spectrum of myeloma patients treated at the Royal Marsden Hospital was probably population based and similar to that of most other tertiary care centers specializing in the treatment of myeloma. Since these patients were treated over a period of nearly 20 years, karyotype data in our series relating to chromosome 13 abnormalities were very limited. However, since our large patient population is comparable to patients treated in Arkansas, one would expect a similar representation of patients with high-risk karyotypes, and the lack of karyotype data should not affect interpretation of outcome data.
Data relating to the state of complete remission are also skewed because the definition of CR has changed markedly over 20 years. The Royal Marsden Hospital group was the first to document CR 1 and later formally define CR 16 in myeloma. The test chosen at the time to determine CR was immunoelectrophoresis, because the more sensitive immunofixation -today's gold standard was not then available. Patients who have attained CR by our original criteria 16 overestimate the incidence of CR as defined by the Blade criteria. 17 They are designated as CR/near-CR since it is impossible to separate the two response categories retrospectively. We switched to immunofixation testing from January 2001 onwards.
Elevated b2-microglobulin, older age and lower albumin prior to autotransplantation are known to be adverse prognostic features. 4, 5, 11, 23 The identification of albumin as a prognostic marker probably reflects its value in characterizing a patient's overall condition at the time of autografting. The fact that albumin affected OS but not EFS suggests that good albumin levels identify patients who tolerate salvage therapy better following relapse after the autograft.
The TRM of 5.9% in this series is high for autotransplantation possibly due to the study period extending from 1985 to 2001 and the inclusion of patients with a creatinine clearance o20 ml/min/m 2 (measured just before they received melphalan 200 mg/m 2 ). With the optimization of autotransplantation (reduction of the dose of melphalan in patients with renal failure to 100-140 mg/m 2 , reinfusion of higher numbers of CD34 þ cells, use of PBSC rather than marrow and improved supportive care in terms of blood products and antibiotics), TRM in our hands is currently less than 3%.
Although the role of high-dose therapy in myeloma has now been clearly established 5, 6 the issue of whether a second 'tandem' transplant confers further advantage is not resolved. Our results, in terms of OS, are comparable to the Arkansas Total Therapy data but inferior in terms of EFS. The Little Rock group has reported a series of 231 patients treated on an intent-to-treat basis with tandem autotransplantation and shown that the median OS/EFS is 68/43 months. 4 The median EFS was shorter in our patients (28 vs 43 months) possibly because of a higher proportion of patients being stage III (73 vs 53%). Also, it is quite possible that the depth of remission is better with tandem transplantation and may increase the proportion of patients who continue in long-term first remission. The second transplant may also be picking up early relapses at the time of second transplant.
With the tandem transplantation approach, 71-85% of patients have gone on to receive the second transplant, 4, 22 whereas in our series, only 26% received a second transplant. Tandem transplants have now been examined in a randomized multicenter setting. The recent French study showed superiority of tandem transplantation over single transplantation. 7 The major shortcoming of the French study was the use of a conditioning regimen (140 mg/m 2 melphalan together with total-body irradiation) for the single transplant arm that has been shown to be marginally inferior to 200 mg/m 2 melphalan 2,24,25 and which could have biased outcome against the single transplant arm. It is noteworthy that the Bologna study, which used 200 mg/m 2 melphalan for the single transplant arm, found OS to be comparable with single and double transplants, although EFS was superior with double transplants. 8 We conclude that a single planned autograft with 200 mg/m 2 melphalan as conditioning results in excellent outcome in myeloma. This could possibly be further enhanced by defining the optimum post-autotransplant treatment including planned and disciplined salvage therapy as an alternative to tandem transplants. A second autograft may be appropriate salvage therapy in a proportion of patients, but the number of suitable patients may decline as more effective nontransplant salvage therapy options become available. The MRC IX trial and others are addressing some of these issues and this study may help in the design of other national and international studies to come.
